EXCEED THE SPACE PROVIDED. A defect in Fas (Ipr mice) or FasL (gld mice) gene causes lupus-like autoimmune disease and accumulationof an abnormal DN T cell population bearing the TCR+CD4'CD8'B220+ surface phenotype. Activation-induced T cell death mediated by Fas/FasL, is a critical mechanism that contains autoreactive T cells and the DN T cells. Studies ofIl-2/Il- 2R gene knockout mice have revealed a correlation of an impaired FasL expression with autoimmune diseases. However, these mice do not accumulate the abnormal DN T cells and their autoimmune phenotype is different from Ipr and gld mice. We propose that IL-2 plays a dual role in the development of autoimmune disease. Initially IL-2 is required for the expansion of autoreactive T cells. Subsequently, IL-2 sensitizes activated T cells in such a way that a TCR re-ligationwill optimally activatefasl gene. FasL is produced to induce apoptosis of the activated T cells, including autoreactiveT cells. We propose thatfasl gene activation requires two signals sequentially deliveredthrough IL-2R and TCR. The cooperation between the two signals can be defined at the level of transcription factors that regulatefasl gene. We propose that the accumulation of autoreactive T cells and the abnormal DN T cells is dependent on IL-2. We have generated [II-2(-/-),fas(-/-)] mice. They do not develop /pr-like autoimmune disease and they do not accumulate the DN T cells. In addition, we propose that the abnormal DN T cells and autoreactive T cells in gld mice are sensitized to FasL and could be selectively eliminated by FasL. We have generated FasL-expressing bioactive vesicles (FasL VP), which displays potent FasL cytotoxicity and selectively kills the abnormal DN T cells. We have 3 specific aims. (1) Demonstrate a two-signal event for optimalfasl gene activation and define the specific and collaborative utilization of transcription.factors involved. (2) Determine how IL-2 regulates the developmentand deletion of the abnormal DN T cells and autoreactive T cells. (3) Demonstrate that FasL VP can delete both the DN T cells and the autoreactive T cells of gld mice and can be used to treat lupus erythematosus in animal models. PERFORMANCE SITE ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI036938-11
Application #
6899240
Study Section
Special Emphasis Panel (ZRG1-SSS-4 (10))
Program Officer
Johnson, David R
Project Start
1995-06-01
Project End
2007-05-31
Budget Start
2005-06-01
Budget End
2007-05-31
Support Year
11
Fiscal Year
2005
Total Cost
$296,000
Indirect Cost
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Chan, Derek V; Sharma, Rahul; Ju, Chiao-Ying A et al. (2013) A recombinant scFv-FasLext as a targeting cytotoxic agent against human Jurkat-Ras cancer. J Biomed Sci 20:16
Sharma, Rahul; Zheng, Lingjie; Deshmukh, Umesh S et al. (2007) A regulatory T cell-dependent novel function of CD25 (IL-2Ralpha) controlling memory CD8(+) T cell homeostasis. J Immunol 178:1251-5
Sharma, R; Zheng, L; Guo, X et al. (2006) Novel animal models for Sjogren's syndrome: expression and transfer of salivary gland dysfunction from regulatory T cell-deficient mice. J Autoimmun 27:289-96
Sung, Sun-Sang J; Fu, Shu Man; Rose Jr, C Edward et al. (2006) A major lung CD103 (alphaE)-beta7 integrin-positive epithelial dendritic cell population expressing Langerin and tight junction proteins. J Immunol 176:2161-72
Jodo, Satoshi; Pidiyar, Vyankatesh J; Xiao, Sheng et al. (2005) Fas ligand (CD178) cytoplasmic tail is a positive regulator of Fas ligand-mediated cytotoxicity. J Immunol 174:4470-4
Xiao, Sheng; Deshmukh, Umesh S; Jodo, Satoshi et al. (2004) Novel negative regulator of expression in Fas ligand (CD178) cytoplasmic tail: evidence for translational regulation and against Fas ligand retention in secretory lysosomes. J Immunol 173:5095-102
Xiao, Sheng; Zhang, Xingmin; Mann, Koren K et al. (2004) Changes in sensitivity of peripheral lymphocytes of autoimmune gld mice to FasL-mediated apoptosis reveal a mechanism for the preferential deletion of CD4-CD8-B220+ T cells. Int Immunol 16:759-66
Jodo, Satoshi; Kung, John T; Xiao, Sheng et al. (2003) Anti-CD95-induced lethality requires radioresistant Fcgamma RII+ cells. A novel mechanism for fulminant hepatic failure. J Biol Chem 278:7553-7
Xiao, Sheng; Sung, Sun-Sang J; Fu, Shu Man et al. (2003) Combining Fas mutation with interleukin-2 deficiency prevents Colitis and Lupus: implicating interleukin-2 for auto-reactive T cell expansion and Fas ligand for colon epithelial cell death. J Biol Chem 278:52730-8
Xiao, Sheng; Jodo, Satoshi; Sung, Sun-Sang J et al. (2002) A novel signaling mechanism for soluble CD95 ligand. Synergy with anti-CD95 monoclonal antibodies for apoptosis and NF-kappaB nuclear translocation. J Biol Chem 277:50907-13

Showing the most recent 10 out of 25 publications